ABVX
Income statement / Annual
Last year (2025), Abivax's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Abivax's net income was -$322.84 M.
See Abivax,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$10.79 M |
$4.62 M |
$4.58 M |
$37.00 K |
$63.00 K |
$2.00 K |
$18.00 K |
$10.00 K |
$127.00 K |
| Cost of Revenue |
$1.03 M
|
$0.00
|
$0.00
|
$110.00 K
|
$156.00 K
|
$33.78 M
|
$28.19 M
|
$68.00 K
|
$14.51 M
|
$14.65 M
|
| Gross Profit |
-$1.03 M
|
$10.79 M
|
$4.57 M
|
$4.47 M
|
-$119.00 K
|
-$33.77 M
|
-$28.19 M
|
-$50.00 K
|
-$6.00 K
|
-$14.52 M
|
| Gross Profit Ratio |
0
|
1
|
0.99
|
0.98
|
-3.22
|
-536.02
|
-14093
|
-2.78
|
-0.6
|
-114.31
|
| Research and Development Expenses |
$170.75 M
|
$146.53 M
|
$103.18 M
|
$48.73 M
|
$47.78 M
|
$34.53 M
|
$29.01 M
|
$15.89 M
|
$0.00
|
$15.46 M
|
| General & Administrative Expenses |
$0.00
|
$32.95 M
|
$28.11 M
|
$7.49 M
|
$5.58 M
|
$5.60 M
|
$4.89 M
|
$4.30 M
|
$3.78 M
|
$3.56 M
|
| Selling & Marketing Expenses |
$0.00
|
$5.95 M
|
$709.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$68.96 M
|
$38.90 M
|
$28.82 M
|
$7.49 M
|
$5.58 M
|
$5.60 M
|
$4.89 M
|
$4.30 M
|
$3.78 M
|
$3.56 M
|
| Other Expenses |
$0.00
|
-$1.66 M
|
-$47.00 K
|
$0.00
|
-$11.96 M
|
-$35.89 M
|
-$28.80 M
|
-$15.62 M
|
-$10.59 M
|
$160.00 K
|
| Operating Expenses |
$239.70 M
|
$183.78 M
|
$127.38 M
|
$56.54 M
|
$42.60 M
|
$4.23 M
|
$5.11 M
|
$19.06 M
|
$4.03 M
|
$3.72 M
|
| Cost And Expenses |
$240.73 M
|
$183.78 M
|
$131.95 M
|
$56.65 M
|
$42.60 M
|
$38.07 M
|
$33.32 M
|
$19.13 M
|
$14.51 M
|
$18.36 M
|
| Interest Income |
$5.38 M
|
$0.00
|
$2.77 M
|
$0.00
|
$84.00 K
|
$0.00
|
$14.00 K
|
$79.00 K
|
$116.00 K
|
$301.00 K
|
| Interest Expense |
$27.39 M
|
$4.18 M
|
$13.83 M
|
$6.94 M
|
$3.56 M
|
$2.06 M
|
$1.59 M
|
$469.00 K
|
$0.00
|
$42.00 K
|
| Depreciation & Amortization |
$1.03 M
|
$1.10 M
|
$707.00 K
|
$485.00 K
|
$156.00 K
|
$66.00 K
|
$80.00 K
|
$99.00 K
|
$93.00 K
|
$66.00 K
|
| EBITDA |
-$239.70 M |
-$171.88 M |
-$133.21 M |
-$53.32 M |
-$38.59 M |
-$38.00 M |
-$33.22 M |
-$19.23 M |
-$13.98 M |
-$18.16 M |
| EBITDA Ratio |
0
|
-15.93
|
-28.83
|
-11.63
|
-1043.03
|
-603.16
|
-16611
|
-1068.17
|
-1398
|
-142.95
|
| Operating Income Ratio |
0
|
-16.03
|
-27.56
|
-14.15
|
-1118.92
|
-603.3
|
-16648
|
-1061.56
|
-1415
|
-143.59
|
| Total Other Income/Expenses Net |
-$79.43 M
|
-$3.26 M
|
-$20.36 M
|
$4.10 M
|
-$1.05 M
|
-$2.12 M
|
-$1.59 M
|
-$483.00 K
|
$77.00 K
|
$258.00 K
|
| Income Before Tax |
-$320.16 M
|
-$176.24 M
|
-$152.23 M
|
-$74.32 M
|
-$42.45 M
|
-$40.13 M
|
-$34.89 M
|
-$19.57 M
|
-$14.07 M
|
-$17.98 M
|
| Income Before Tax Ratio |
0
|
-16.33
|
-32.94
|
-16.22
|
-1147.35
|
-636.94
|
-17445
|
-1087.11
|
-1407.3
|
-141.56
|
| Income Tax Expense |
$2.68 M
|
$0.00
|
-$4.49 M
|
-$4.48 M
|
$0.00
|
-$2.58 M
|
-$4.26 M
|
-$3.77 M
|
-$2.69 M
|
-$3.52 M
|
| Net Income |
-$322.84 M
|
-$176.24 M
|
-$147.74 M
|
-$60.74 M
|
-$42.45 M
|
-$37.55 M
|
-$30.63 M
|
-$15.82 M
|
-$11.22 M
|
-$14.31 M
|
| Net Income Ratio |
0
|
-16.33
|
-31.97
|
-13.25
|
-1147.35
|
-596.05
|
-15317
|
-879.06
|
-1122.3
|
-112.66
|
| EPS |
-4.65 |
-2.8 |
-3.43 |
-3.18 |
-2.75 |
-2.62 |
-2.51 |
-1.56 |
-1.14 |
-1.48 |
| EPS Diluted |
-4.65 |
-2.8 |
-3.43 |
-3.18 |
-2.75 |
-2.62 |
-2.51 |
-1.55 |
-1.13 |
-1.47 |
| Weighted Average Shares Out |
$69.53 M
|
$63.05 M
|
$43.07 M
|
$19.09 M
|
$15.46 M
|
$14.31 M
|
$12.18 M
|
$10.18 M
|
$9.87 M
|
$9.65 M
|
| Weighted Average Shares Out Diluted |
$69.53 M
|
$63.05 M
|
$43.07 M
|
$19.09 M
|
$15.46 M
|
$14.31 M
|
$12.18 M
|
$10.21 M
|
$9.93 M
|
$9.73 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
